Aurigene Pharmaceutical's Rs 330 crore plant in Hyderabad Genome Valley.
The Aurigene Pharmaceutical Services Ltd. facility in Hyderabad will be a cutting-edge development and manufacturing centre for therapeutic proteins, antibodies, and viral vectors. Aurigene is a leading contract research, development, and manufacturing services organisation and a step-down subsidiary of Dr. Reddy's Laboratories.
IT and Industries Minister KT Rama Rao was briefed by Dr. Reddy's Laboratories Chairman Satish Reddy and Aurigene Pharmaceuticals Services Limited CEO Akhil Ravi on Tuesday about the new facility and Aurigene's expansion plans in Hyderabad.
The expenditure of $40 million (about Rs.330 crore) was justified, they maintained, because of the project's principal aim: creating new jobs.
Within the next three years, they intend to invest enough money to create roughly 200 new direct jobs and an additional 60-70 indirect jobs.
The company plans to significantly boost its investments in the future, which should lead to a multiplicative increase in employment opportunities in cutting-edge scientific and manufacturing fields.
According to an official release, Aurigene wants to further develop the facility by exploring innovative therapeutics, in particular cell and gene therapies.
I am thrilled that Aurigene has decided to locate their cutting-edge research and production centre in Genome Valley. The State government's goal of improving 'complex manufacturing at scale' in order to take a great step towards more sophisticated therapeutic modalities is exactly in line with this investment. Hyderabad's position as a preferred destination for biopharmaceutical research and production has been bolstered by Aurigene's investment in biotherapeutics discovery, the Minister said.
The Minister went on to say that Aurigene's investment would not only contribute to the growth of the biotherapeutics Contract Development and Manufacturing Organisation (CDMO) ecosystem in Hyderabad, but would also reinforce the State government's vision to enhance and promote the biologics capabilities of th.
Comments